113
Views
2
CrossRef citations to date
0
Altmetric
Articles

Anti-inflammatory effect of dialysable leucocyte extract in a rat model of osteoarthritis: histopathological and molecular characterization

, , , , , , & show all
Pages 528-535 | Accepted 08 Feb 2016, Published online: 21 Apr 2016

References

  • Martel-Pelletier J, Boileau C, Pelletier J-P. Cartilage in normal and osteoarthritis conditions. Best Pract Res Clin Rheumatol 2008;22:351–84.
  • Arden N, Nevitt N. Osteoarthritis, epidemiology. Best Pract Res Clin Rheumatol 2006;20:3–25.
  • Lories R, Luyten F. The bone–cartilage unit in osteoarthritis. Nat Rev Rheumatol 2011;7:43–9.
  • Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol 2011;7:33–42.
  • Martel-Pelletier J. The interleukin-1 receptor in normal and osteoarthritic human articular chondrocytes. Identification as the type I receptor and analysis of binding kinetics and biologic function. Arthritis Rheum 1992;35:530–40.
  • Blom AB, van der Kraan PM, van den Berg WB. Cytokine targeting in osteoarthritis. Curr Drug Targets 2007;8:283–92.
  • Shimoaka T, Ogasawara T, Yonamine A. Regulation of osteoblast, chondrocyte, and osteoclast functions by fibroblast growth factor (FGF)-18 in comparison with FGF-2 and FGF-10. J Biol Chem 2002;277:7493–500.
  • Michael JW, Schlüter-Brust KU, Eysel P. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee. Dtsch Arztebl Int 2010;107:152–62.
  • Fudenberg H, Pizza G. Transfer factor 1993, new frontiers. Prog Drug Res 1994;42:309–400.
  • Kirkpatrick CH, Gallin JI. Suppression of cellular immune responses following transfer factor: report of a case. Cell Immunol 1975;15:470–4.
  • Kirkpatrick CH, Rozzo SJ, Mascali JJ. Murine transfer factor. III. Specific interactions between transfer factor and antigen. J Immunol 1985;135:4027–33.
  • Kirkpatrick CH. Transfer factors, identification of conserved sequences in transfer factor molecules. Mol Med 2000;64:332–41.
  • Ojeda MO, Van’t Veer C, Fernández CB, Araña MJ, Buurman WA. Dialyzable leukocyte extract differentially regulates the production of TNFalpha, IL-6, and IL-8 in bacterial component-activated leukocytes and endothelial cells. Inflamm Res 2005;5:74–81.
  • Pineda B, Estrada-Parra S, Pedraza-Medina B, Rodriguez-Ropon A, Pérez R, Arrieta O. Interstitial transfer factor as adjuvant immunotherapy for experimental glioma. J Exp Clin Cancer Res 2005;24:575–83.
  • Pizza G, Chiodo F, Colangeli V, Gritti F, Raise E, Fudenberg HH. et al. Preliminary observations using HIV-specific transfer factor in AIDS. Biotherapy 1996;9:41–7.
  • Pizza G, De Vinci C, Cuzzocrea D, Menniti D, Aiello E, Maver P. et al. A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer. Biotherapy 1996;9:123–32.
  • Pizza G. In vitro studies during long‐term oral administration of specific transfer factor. Biotherapy 1996;9:175‐85.
  • Cordero M, Flores G, Orea M, Estrada S, Serrano E. Safety and efficacy of treatment for severe atopic dermatitis with cyclosporin A and transfer factor. Rev Alerg Mex 1999;46:49–57.
  • Dvoroznáková E, Porubcová J, Sevcíková Z. Immune response of mice with alveolar echinococcosis to therapy with transfer factor, alone and in combination with albendazole. Parasitol Res 2009;105:1067–76.
  • Espinosa S, Orozco S, Plaza A, Estrada S, Estrada I, et al. [Effect of transfer factor on treatment with glucocorticoids in a group of pediatric patients with persistent moderate allergic ashma], in Spanish. Rev Alerg Mex 2009;56:67–71.
  • Cabezas Quiroga R, Estrada Parra S, Padierna L, Padierna J, Fernández C, López P. [Immunotherapy with transfer factor in patients with herpes zoster], in Spanish. P. Biotechnol ap 1990;7:52–7, 1990.
  • Estrada-Parra S, Nagaya A, Serrano E, Rodriguez O, Santamaria V, Ondarza R, et al. Comparative study of transfer factor and acyclovir in the treatment of herpes zoster. Int J Immunopharmacol 1998;20:521–35.
  • Georgescu C. Effect of long-term therapy with transfer factor in rheumatoid arthritis. Med Interne 1985;23:135–40.
  • Stanciková M, Rovenský J, Pekárek J, Orviský E, Blazícková S. et al. Influence of various forms of dialyzable leukocyte extracts on rat adjuvant arthritis. Arch Immunol Ther Exp 1994;42:295–9.
  • Lozoya K, Kouri J. A novel rat osteoarthrosis model to assess apoptosis and matrix degradation. Pathol Res Pract 2000;196:729–45.
  • Montrull H, Brizuela N, Demurtas S, Spitale L, Meirovich C. Structure and secretory activity of cultured chondrocytes from patients with osteoarthritis. Biocell 2005;29:163–7.
  • Pritzker KP, Gay S, Jimenez SA, Ostergaard K, Pelletier JP, Revell PA, et al. Osteoarthritis cartilage histopathology: grading and staging. Osteoarthritis Cartilage 2006;14:13–29.
  • Sophia Fox AJ, Bedi A, Rodeo SA. The basic science of articular cartilage: structure, composition, and function. Sports Health 2009;6:461–8.
  • Boileau C, Martel-Pelletier J, Caron J, Msika P, Guillou GB, Baudouin C, et al. Protective effects of total fraction of avocado/soybean unsaponifiables on the structural changes in experimental dog osteoarthritis: inhibition of nitric oxide synthase and matrix metalloproteinase-13. Arthritis Res Ther 2009;11:1–9.
  • Bunning RA, Russell RG. The effect of tumor necrosis factor alpha and gamma-interferon on the resorption of human articular cartilage and on the production of prostaglandin E and of caseinase activity by human articular chondrocytes. Arthritis Rheum 1989;32:780–4.
  • Guillen S, Mirabeth L. [Chondrocyte differentiation in rich plasma platelet growth factors for articular chondroplasty], in Spanish. Patología del aparato locomotor 2005;3:13–23.
  • Grassi F, Piacentini A, Cristino S, Toneguzzi S, Facchini A, Lisienoli G. et al. Inhibition of CD95 apoptotic signaling by interferon-gamma in human osteoarthritic chondrocytes is associated with increased expression of FLICE inhibitory protein. Arthritis Rheum 2004;50:498–506.
  • Muddasani P, Norman JC, Ellman M, van Wijnen AJ, Im HJ. Basic fibroblast growth factor activates the MAPK and NFkappaB pathways that converge on Elk-1 to control production of matrix metalloproteinase-13 by human adult articularchondrocytes. J Biol Chem 2007;282:31409–21.
  • Civinini R, Nistri L, Martini C, Redl B, Ristori G, Innocenti M. Growth factors in the treatment of early osteoarthritis. Clin Cases Miner Bone Metab 2013;10:26–9.
  • Fortier LA, Barker JU, Strauss EJ, McCarrel TM, Cole BJ. The role of growth factors in cartilage repair. Clin Orthop Relat Res 2011;469:2706–15.
  • Kwon DR, Park GY. Intra-articular injections for the treatment of osteoarthritis: focus on the clinical use of several regimens. In: Chen Q, editor. Osteoarthritis – diagnosis, treatment and surgery. InTech, 2012;67–100 (http://cdn.intechopen.com/pdfs-wm/30683.pdf). Accessed 24 February 2016.
  • Saklatvala J. Inflammatory signaling in cartilage, MAPK and NF-κB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Curr Drug Targets 2007;8:305–13.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.